Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 3/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.37 |
| ▸ | DPP4 | P27487 | 6/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14624185 | 0.83 | CPN1 (0.41) | CPN1CPB2DPP4DPP8DPP9 | |
| SCHEMBL18705550 | 0.80 | CPN1 (0.36) | CPN1CPB2DPP4DPP8DPP9 | |
| SCHEMBL8513454 | 0.79 | CPN1 (0.37) | CPN1CPB2DPP4DPP8DPP9 | |
| SCHEMBL27863433 | 0.77 | CPN1 (0.39) | CPN1CPB2DPP4DPP8DPP9 | |
| SCHEMBL5598021 | 0.75 | DPP4 (0.51) | DPP4 | |
| SCHEMBL18693474 | 0.75 | DPP4 (0.51) | DPP4 | |
| SCHEMBL18693473 | 0.75 | DPP4 (0.51) | DPP4 | |
| SCHEMBL19030414 | 0.74 | CPN1 (0.34) | CPN1CPB2DPP4DPP7 | |
| SCHEMBL5993908 | 0.74 | CPN1 (0.39) | CPN1CPB2DPP4DPP8DPP9 | |
| SCHEMBL5994169 | 0.74 | CPN1 (0.39) | CPN1CPB2DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017060873-A1 | SUBSTITUTED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXYLIC ACIDS AND THEIR USE | AbbVie S.à.r.l. (LU) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017060874-A1 | N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE S.Á.R.L (LU) | 2017-04-13 | — | — | WO | disclosed |
| US-7265249-B2 | Enantioselective alpha-fluorination of aldehydes using chiral organic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-09-04 | — | — | US | disclosed |
| US-20060189830-A1 | Enantioselective alpha-fluorination of aldehydes using chiral organic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189830-A1 | Enantioselective alpha-fluorination of aldehydes using chiral organic catalysts | ALDH3A1, ALDH1A1, POLL | CPN1 643/4885CPB2 3222/4885DPP4 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.